Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance

Di Liu, Xinyan Xu, Junmiao Wen, Chi Zhang, Min Fan

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown a high response rate and long progression-free survival in primary treatment of ALK-positive non-small-cell lung cancer (NSCLC). De novo resistance or refractory subtype is rare event. Herein, we identify the first case with serial next-generation sequencing (NGS) results that harboured a rare echinoderm microtubule associated protein like 4 gene (EML4) -ALK (breaking site at exon 19) fusion in a lung adenocarcinoma (LUAD) patient who acquired alectinib resistance rapidly (less than 3 months), followed by multi-drug resistance and short survival time.

Original languageEnglish (US)
Pages (from-to)32-35
Number of pages4
JournalLung Cancer
Volume160
DOIs
StatePublished - Oct 2021

Keywords

  • ALK TKIs
  • ALK variants
  • Case report
  • Lung cancer

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint

Dive into the research topics of 'Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance'. Together they form a unique fingerprint.

Cite this